Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Distinct trajectory and prognosis of measurable residual disease (MRD) in t(11;14) multiple myeloma (MM) treated with upfront quadruplet (QUAD) therapy and autologous stem cell transplantation (ASCT)

View Full Paper
Ask AI
Bookmark
Share

Authors

LCLuciano da Fontoura CostaFHForest HulsEMEva Medvedova

Discussion

Loading...

Member takes

Overview

Analysis reveals that QUAD therapy improves progression-free survival in t(11;14) multiple myeloma, suggesting effective MRD management strategies.

Key Points

  • To compare measurable residual disease dynamics and prognosis in t(11;14) multiple myeloma after QUAD therapy and ASCT.
  • Analyzed data from 302 newly diagnosed multiple myeloma patients receiving QUAD and ASCT.
  • Assessed MRD post induction, post ASCT, and yearly thereafter.
  • Utilized Cox regression for predictive modeling of disease progression based on MRD.
  • MRD negativity rate was 9% for t(11;14)pos vs. 31% for t(11;14)neg at post induction (P=0.01).
  • Four-year progression-free survival was 93% in t(11;14)pos vs. 73% in t(11;14)neg (P=0.017).
  • Both S-MRD negativity and t(11;14)pos status are associated with lower risk of progression or death.

Cite This Study

Costa et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0eahttps://doi.org/10.1182/blood-2025-363
View Full Paper
Ask AI
Bookmark
Share